Company Overview and News

1
Malaysia’s top 40 richest people

2018-02-03 thestar.com.my
LAST year was dotted by the return of higher commodity prices and better economic growth. The world’s economies on average are back in business as growth rates and trade have started to improve once again after some period of uncertainty caused by a cooling China economy and also the slump in global crude oil prices.

2
Top 40 richest in Malaysia: 21-25

2017-02-04 thestar.com.my
KIAN CHONG, 40, is the grandson of the late Tan Sri Loh Boon Siew, who in his lifetime was the richest man in Penang.

 
Tan Chong's car sales up but half-year earnings fall 31%

2016-08-30 business.asiaone
A slowing Asian automotive industry and the stronger Japanese yen sent half-year earnings tumbling at motor distributor Tan Chong International.

 
Second Chance, Tan Chong, Stratech, YuuZoo, KS Energy

2016-03-31 theedgemarkets
Second Chance Properties’ net profit for the second quarter fell 64% to $1.1 million on lower revenue and gains from the fair valuation of properties. Revenue for the three months ended Feb fell 16% to $8.4 million. Its fair value gains on properties dropped by half to $553,000, while the loss on fair valuation of assets widened from $690,000 to $1.58 million. The counter closed at 24.5 cents on Wednesday.

 
Tan Chong full-year net profit dips 11.7 per cent

2016-03-30 straitstimes
Motor vehicle company Tan Chong International recorded an 11.7 per cent drop in full-year net profit, thanks to valuation losses on investment properties, as well as currency volatility.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...